UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Anti-CD20 monoclonal antibodies in Systemic Lupus Erythematosus

Shah, K; Cragg, M; Leandro, M; Reddy, V; (2021) Anti-CD20 monoclonal antibodies in Systemic Lupus Erythematosus. Biologicals , 69 pp. 1-14. 10.1016/j.biologicals.2020.11.002. Green open access

[thumbnail of Shah_Revised Manuscript 041020 without highlighted.pdf]
Preview
Text
Shah_Revised Manuscript 041020 without highlighted.pdf - Accepted Version

Download (254kB) | Preview

Abstract

Systemic Lupus Erythematosus (SLE) is an autoimmune inflammatory condition with a wide spectrum of disease manifestations and severities, resulting in significant morbidity and mortality. The aetiopathogenesis of SLE is complex. Young women and certain ethnicities are commonly affected, suggesting a significant hormonal and genetic influence. Diverse immunological abnormalities have been described. A characteristic abnormality is the presence of autoantibodies, implicating a central role for B cells in disease pathogenesis and/or perpetuation. Whilst conventional therapies have improved outcomes, a great unmet need remains. Recently, biological therapies are being explored. B-cell depletion therapy with rituximab has been in use off-label for nearly two decades. Inconsistent results between uncontrolled and controlled studies have raised doubts about its efficacy. In this review, we will focus on B cell abnormalities and the rationale behind B-cell depletion therapy with anti-CD20 monoclonal antibody (mAb), rituximab, will be explored including an evaluation of clinical and trial experience. Finally, we will discuss the mechanistic basis for considering alternative anti-CD20 mAbs.

Type: Article
Title: Anti-CD20 monoclonal antibodies in Systemic Lupus Erythematosus
Open access status: An open access version is available from UCL Discovery
DOI: 10.1016/j.biologicals.2020.11.002
Publisher version: https://doi.org/10.1016/j.biologicals.2020.11.002
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
Keywords: Lupus, Biologic, B cell therapy, Anti-CD20 monoclonal antibody, Rituximab
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Inflammation
URI: https://discovery.ucl.ac.uk/id/eprint/10128636
Downloads since deposit
43Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item